The Development and Treatment Potential of FTX-6058

Conference|ASH Annual Meeting and Exposition - American Society of Hematology Annual Meeting and Exposition

Pharmacy Times® interviewed Christopher Moxham of Fulcrum Therapeutics, on what FTX-6058 is, how it was developed, and what it is able to treat.

Pharmacy Times^® interviewed Christopher Moxham, the senior vice president of discovery research at Fulcrum Therapeutics, on his presentation at the 62nd ASH Annual Meeting and Exposition. The presentation discusses research into the induction of fetal hemoglobin by FTX6058, a novel small molecule development candidate.

In this video, Moxham explains what FTX-6058 is, how it was developed, and what it is able to treat.